IMMUNOME INC (IMNM) Stock Price, Quote, News and Overview
NASDAQ:IMNM - Nasdaq - US45257U1088 - Common Stock - Currency: USD
IMNM Quote, Performance and Key Statistics
9.4
+0.51 (+5.74%)
The current stock price of IMNM is 9.4 USD. In the past month the price decreased by -10.56%. In the past year, price decreased by -63.06%.
IMNM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.66 | 369.39B | ||
| AMGN | AMGEN INC | 15.54 | 165.43B | ||
| GILD | GILEAD SCIENCES INC | 24.8 | 142.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1654.45 | 123.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.31 | 76.39B | ||
| ARGX | ARGENX SE - ADR | 242.12 | 37.96B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.83B | ||
| ONC | BEIGENE LTD-ADR | N/A | 29.00B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.07B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| BIIB | BIOGEN INC | 8.53 | 20.47B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.26B |
Related stock screener links
About IMNM
Company Profile
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Bothell, Washington and currently employs 55 full-time employees. The company went IPO on 2020-10-02. The firm's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. The company also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.
Company Info
IMMUNOME INC
18702 N. Creek Parkway, Suite 100
Bothell WASHINGTON 19341 US
CEO: Purnanand D. Sarma
Employees: 78
Company Website: https://immunome.com/
Investor Relations: http://investors.immunome.com
Phone: 16103213700
IMMUNOME INC / IMNM FAQ
What is the stock price of IMMUNOME INC today?
The current stock price of IMNM is 9.4 USD. The price increased by 5.74% in the last trading session.
What is the ticker symbol for IMMUNOME INC stock?
The exchange symbol of IMMUNOME INC is IMNM and it is listed on the Nasdaq exchange.
On which exchange is IMNM stock listed?
IMNM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMUNOME INC stock?
13 analysts have analysed IMNM and the average price target is 30.6 USD. This implies a price increase of 225.53% is expected in the next year compared to the current price of 9.4. Check the IMMUNOME INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMUNOME INC worth?
IMMUNOME INC (IMNM) has a market capitalization of 749.93M USD. This makes IMNM a Small Cap stock.
How many employees does IMMUNOME INC have?
IMMUNOME INC (IMNM) currently has 78 employees.
What are the support and resistance levels for IMMUNOME INC (IMNM) stock?
IMMUNOME INC (IMNM) has a support level at 9.39 and a resistance level at 10.67. Check the full technical report for a detailed analysis of IMNM support and resistance levels.
Is IMMUNOME INC (IMNM) expected to grow?
The Revenue of IMMUNOME INC (IMNM) is expected to decline by -23.24% in the next year. Check the estimates tab for more information on the IMNM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMMUNOME INC (IMNM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMNM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMNM, evaluating the profitability, health, valuation and growth aspects
- IMMUNOME INC (IMNM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUNOME INC (IMNM) Sales and EPS estimates to see what analysts future expectations are.
- IMMUNOME INC (IMNM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUNOME INC (IMNM) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUNOME INC (IMNM) Stock Chart to make your own analysis
- IMMUNOME INC (IMNM) Latest news and press-releases to stay up to date.
Does IMMUNOME INC (IMNM) stock pay dividends?
IMNM does not pay a dividend.
When does IMMUNOME INC (IMNM) report earnings?
IMMUNOME INC (IMNM) will report earnings on 2025-03-26, after the market close.
What is the Price/Earnings (PE) ratio of IMMUNOME INC (IMNM)?
IMMUNOME INC (IMNM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.89).
What is the Short Interest ratio of IMMUNOME INC (IMNM) stock?
The outstanding short interest for IMMUNOME INC (IMNM) is 13.39% of its float. Check the ownership tab for more information on the IMNM short interest.
IMNM Technical Analysis
IMNM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMNM. IMNM has a great financial health rating, but its profitability evaluates not so good.
IMNM Financial Highlights
Over the last trailing twelve months IMNM reported a non-GAAP Earnings per Share(EPS) of -7.89. The EPS decreased by -234.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -118.86% | ||
| ROE | -142.08% | ||
| Debt/Equity | 0 |
IMNM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to IMNM. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -346.4% and a revenue growth -23.24% for IMNM